TauRx reportedly in partnership talks for Rember

The largely unknown TauRx has been basking in the limelight of some startling efficacy data for its experimental Alzheimer's drug--Rember. TauRx was founded by research scientists at Aberdeen University who opted to base the company in Singapore, where officials were willing to provide funding without the kind of stinging equity bite the UK venture crowd was demanding.

Now TauRx officials tell The Times that ongoing discussions may soon lead to new partnerships for the fledgling biotech. The IP for Rember is entirely owned by TauRx, but that may soon change.

- read the article from The Times

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.